Under the Paperwork Reduction Act of 1995, no persons are required to respond to

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10691851
Filing Date			2003-10-23
	First Named Inventor	Syuji	Tsukamoto
	Art Unit		1725
	Examiner Name	Maria	Alexandra Elve
	Attorney Docket Number		890050.442

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No Patent Number		Kind Code <sup>1</sup> Issue Date		)ate	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Publication Code <sup>1</sup> Date			Name of Patentee or Applicant Rele			ges,Columns,Lines where evant Passages or Relevant ures Appear		
	1										
If you wisl	h to a	dd additional U.S. Publi						d button	Add		
	_		_	FOREK	3N PAT	ENT DOCUM	ENTS				_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Re	or Relevant	т.
	1	2001118288	JP			2001-04-27	Yoshihisa				Г
	2	2002025121	JP			2002-01-25	Masahiro et al.				С
	3	2002032918	JP			2002-01-31	Ryuichi et al.				c

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10691851
Filing Date		2003-10-23
First Named Inventor Syuji		Tsukamoto
Art Unit		1725
Examiner Name	Maria	Alexandra Elve
Attorney Docket Numb	er	890050.442

	4	2002260239	JP		2002-09-13	Којі			
	5	2004030854	JP		2004-01-29	Isao			
If you wisi	h to a	dd additional Forei	gn Patent Document	citation	information p	lease click the Add buttor	Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catabig, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тв		
	1								
If you wis	h to a	dd additional non-p	atent literature docu	ment cit	ation informat	tion please click the Add I	outton Add		
	EXAMINER SIGNATURE								
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

1 See Kind Codes of USPTO Planto Documents at year, USPTO, DOLY or MPEP 901.04. \* Enter office in the issued for a cocument, by the two-letter code (WIPO Standard ST3.). \* For Legislanese plant documents, be induction to the year of the reign of the Engerent must precede the senial number of the plant document. \* Micro of Cocument by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English strapping translations in attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10691851	
Filing Date			2003-10-23	
	First Named Inventor	Syuji	Tsukamoto	
Art Unit			1725	
	Examiner Name	Maria	Alexandra Elve	
	Attorney Docket Number		890050.442	

#### CERTIFICATION STATEMENT

Diagra con	37	CFR .	1 97	and	1 02	to make	the	appropriate	colortion/c	١.

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.57(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_\_ □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.	of the signature.									
Signature	/Raymond W. Armentrout/	Date (YYYY-MM-DD)	2007-03-28							
Name/Print	Raymond W. Armentrout	Registration Number	45.866							

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.